Mark Murphy

Dr. Mark Murphy


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 1993 in Research in Developmental Disabilities
Verified
Journal Article
Closed access
RFRalph P. Ferretti
Ralph P. Ferretti
ACAl R. Cavalier
Al R. Cavalier
MMMark Murphy
Mark Murphy
RMRoberta Murphy
Roberta Murphy

11 September 2020 in RMD Open
Verified
Journal Article
Open access
PDF file
DSDaniel S Strasser
Daniel S Strasser
SFSylvie Froidevaux
Sylvie Froidevaux
VSVirginie Sippel
Virginie Sippel
EGEstelle Gerossier
Estelle Gerossier
UGUrsula Grieder
Ursula Grieder
MMMark Murphy
Mark Murphy
Objectives: SLE is an autoimmune disease characterised by aberrant lymphocyte activation and autoantibody production. This study provides an in-depth preclinical and clinical characterisation of the treatment effect of cenerimod, a sphingosine-1-phosphate receptor type 1 (S1P1) modulator, in SLE. Methods: Cenerimod effect on lymphocyte numbers, organ pathology, inflammation, and survival was evaluated in the MRL/lpr lupus mouse model. Lymphocytes from healthy subjects and patients with SLE were assessed for cenerimod-induced S1P1 receptor internalisation. Lymphocyte subsets and inflammatory biomarkers were characterised in a 12-week phase 2 clinical study (NCT-02472795), where patients with SLE were treated with multiple doses of cenerimod or placebo. Results: In MRL/lpr mice treated with cenerimod, blood lymphocytes were reduced, leading to reduced immune infiltrates into tissue, and decreased tissue pathology, proteinuria, and inflammation, resulting in increased survival. Cenerimod was potent and efficacious in inducing S1P1 receptor internalisation in lymphocytes in both healthy subjects and patients with SLE. In patients with SLE, 12-week cenerimod treatment resulted in a dose-dependent reduction of blood lymphocytes, antibody-secreting cells (ASC), and plasma IFN-α. Conclusion: Cenerimod significantly ameliorated systemic and organ-specific pathology and inflammation in a mouse model of SLE. In lymphocytes from patients with SLE, the S1P1 receptor remained functional despite concomitant background medication. The preclinical lymphocyte reduction translated to patients with SLE and resulted in the normalisation of ASC and the reduction of IFN-associated biomarkers. The efficacy and safety of cenerimod is being further investigated in a long-term clinical study in patients with SLE (CARE; NCT-03742037).

Verified
Journal Article
Open access
PDF file
LSLisa Schlicher
Lisa Schlicher
PKPaulina Kulig
Paulina Kulig
AMAudrey von Münchow
Audrey von Münchow
MMMark Murphy
Mark Murphy
MKMarcel Keller
Marcel Keller
Cenerimod is a potent, selective sphingosine 1-phosphate receptor 1 (S1P1) modulator currently investigated in a Phase IIb study in patients with systemic lupus erythematosus (SLE) (NCT03742037). S1P1 receptor modulators sequester circulating lymphocytes within lymph nodes, thereby reducing pathogenic autoimmune cells (including T and B lymphocytes) in the bloodstream and inflamed tissues, making them an effective therapeutic concept for autoimmune disorders. Although the effect of S1P receptor modulators in reducing circulating lymphocytes is well documented, the precise molecular role of the S1P1 receptor on these cell types is not fully understood. In this study, the mode of action of cenerimod on human primary lymphocytes in different activation states was investigated focusing on their chemotactic behavior towards S1P in real-time, concomitant to S1P1 receptor expression and internalization dynamics. Here, we show that cenerimod effectively prevents T and B cell migration in a concentration-dependent manner. Interestingly, while T cell activation led to strong S1P1 re-expression and enhanced migration; in B cells, an enhanced migration capacity and S1P1 receptor surface expression was observed in an unstimulated state. Importantly, concomitant treatment with glucocorticoids (GCs), a frequently used treatment for autoimmune disorders, had no impact on the inhibitory activity of cenerimod on lymphocytes.

14 November 2009
Verified
Conference Paper
Open access
PDF file
MMMarghoob Mohiyuddin
Marghoob Mohiyuddin
MMMark Murphy
Mark Murphy
LOLeonid Oliker
Leonid Oliker
JSJohn Shalf
John Shalf
JWJohn Wawrzynek
John Wawrzynek
SWSamuel Williams
Samuel Williams

29 November 2021 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
EGEstelle Gerossier
Estelle Gerossier
SNSaba Nayar
Saba Nayar
SFSylvie Froidevaux
Sylvie Froidevaux
CSCharlotte G. Smith
Charlotte G. Smith
CRCeline Runser
Celine Runser
FBFrancesca Barone
Francesca Barone
Background: Sjögren’s syndrome is a systemic autoimmune disease characterized by immune cells predominantly infiltrating the exocrine glands and frequently forming ectopic lymphoid structures. These structures drive a local functional immune response culminating in autoantibody production and tissue damage, associated with severe dryness of mucosal surfaces and salivary gland hypofunction. Cenerimod, a potent, selective and orally active sphingosine-1-phosphate receptor 1 modulator, inhibits the egress of lymphocytes into the circulation. Based on the mechanism of action of cenerimod, its efficacy was evaluated in two mouse models of Sjögren’s syndrome. Methods: Cenerimod was administered in two established models of Sjögren’s syndrome; firstly, in an inducible acute viral sialadenitis model in C57BL/6 mice, and, secondly, in the spontaneous chronic sialadenitis MRL/lpr mouse model. The effects of cenerimod treatment were then evaluated by flow cytometry, immunohistochemistry, histopathology and immunoassays. Comparisons between groups were made using a Mann-Whitney test. Results: In the viral sialadenitis model, cenerimod treatment reduced salivary gland immune infiltrates, leading to the disaggregation of ectopic lymphoid structures, reduced salivary gland inflammation and preserved organ function. In the MRL/lpr mouse model, cenerimod treatment decreased salivary gland inflammation and reduced T cells and proliferating plasma cells within salivary gland ectopic lymphoid structures, resulting in diminished disease-relevant autoantibodies within the salivary glands. Conclusions: Taken together, these results suggest that cenerimod can reduce the overall autoimmune response and improve clinical parameters in the salivary glands in models of Sjögren’s syndrome and consequently may reduce histological and clinical parameters associated with the disease in patients.

24 November 2024
Verified
Journal Article
Closed access
MSMadeleine Suffiotti
Madeleine Suffiotti
PBPijus Brazauskas
Pijus Brazauskas
MKMarcel Keller
Marcel Keller
OBOuali Berkani
Ouali Berkani
GSGustavo Seifer
Gustavo Seifer
DSDaniel Stefan Strasser
Daniel Stefan Strasser